Why has there been a global surge of new Covid variant NB.1.8.1?
India is the latest country to report a surge in new Covid cases, as the latest variant NB.1.8.1 spreads across the globe.
Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UKHSA recorded the first 13 cases in England last week.
However, the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago.
NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year.
It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia.
By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent one month before.
The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus.
Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants.
'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation.
Dr Chun Tang, GP at Pall Mall Medical, added: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity.
'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.'
'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice.
'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.'
However, Nimbus does appear to be more transmissible than previous variants, with notable increases reported in India, Hong Kong, Singapore, and Thailand, notes Dr Asif.
Common symptoms of the NB.1.8.1 variant include a severe sore throat. fatigue, mild cough, fever, muscle aches and congestion.
It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea.
Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Japan Facial Injectables Market Set to Reach Valuation of US$ 1,121.31 Million by 2033
Japan facial injectables market is set to thrives with growth in natural beauty trends, technological innovations, and urban demand. Despite regulatory and rural challenges, cultural shifts and economic factors fuel sustained growth potential. Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The Japan facial injectables market was valued at US$ 508.18 million in 2024 and is projected to reach US$ 1,121.31 million by 2033, growing at a CAGR of 9.52% during the forecast period 2025–2033. The Japan facial injectables market is experiencing a significant shift in consumer behavior with a growing preference for subtle, natural-looking enhancements over dramatic transformations. Younger demographics, particularly those in their 20s and 30s, are increasingly opting for preventative treatments like botulinum toxin to delay signs of aging. Social media platforms, such as Instagram and TikTok, play a pivotal role in shaping beauty ideals, with influencers promoting injectables as a routine part of self-care. Moreover, there is a noticeable rise in male consumers seeking facial injectables, driven by societal acceptance of male grooming and professional competitiveness. Request Sample Pages: This trend aligns with Japan's cultural emphasis on "kawaii" (cuteness) and polished aesthetics, pushing demand for products that enhance facial harmony. According to a 2024 survey by the Japan Aesthetic Medicine Association, over 60,000 men underwent injectable treatments last year, a sharp increase from previous years. Clinics in urban hubs like Tokyo and Osaka report a surge in demand for hyaluronic acid fillers for jawline contouring and under-eye rejuvenation. Additionally, the rise of hybrid work environments has reduced downtime concerns, encouraging more individuals to schedule quick procedures. As consumer awareness grows, brands are focusing on personalized treatment plans, ensuring safety and satisfaction in this evolving landscape of the Japan facial injectables market. Key Findings in Japan Facial Injectables Market Market Forecast (2033) US$1,121.31 million CAGR 9.52% By Product Type Botulinum Toxin/Botox (55.97%) By Age Group 35-50 Year (51.72%) By Gender Female (81.62%) By Clinic Type Dermatology Clinics (35.45%) By Application Wrinkle Reduction (39.97%) Top Drivers Japan's rapidly aging society seeking non-surgical facial rejuvenation solutions Growing acceptance of aesthetic procedures among younger Japanese professionals Advanced injection techniques developed specifically for Asian facial anatomy Top Trends Micro-dosing approaches gaining popularity for natural-looking results in Japan Preventative treatments starting earlier among Tokyo millennials and Gen-Z AI-powered facial analysis integration in Japanese aesthetic clinics nationwide Top Challenges Strict PMDA regulations limiting new product approvals and innovations High training requirements creating certified injector shortages across prefectures Price sensitivity among middle-income consumers limiting market expansion potential Technological Breakthroughs Redefining Aesthetic Treatments In the Japan facial injectables market, technological innovation is a key growth driver with new formulations and delivery methods enhancing treatment precision and outcomes. Advanced micro-droplet injection techniques are gaining popularity for their ability to deliver natural-looking results, particularly for delicate areas like under-eyes. Additionally, AI-powered consultation tools are transforming patient experiences, enabling simulations of post-treatment results. Major brands are also developing longer-lasting fillers with biocompatible materials tailored to Asian skin types. A report by the Japan Society of Aesthetic Surgery (JSAS) indicates that over 92,000 procedures utilized cutting-edge injection technologies last year, reflecting rapid market adoption. For instance, Galderma's latest hyaluronic acid filler, designed for thinner skin textures common in Japanese patients, saw over 30,000 applications in clinics nationwide. The rise of telemedicine platforms has further democratized access, with over 25,000 virtual consultations recorded for injectables in 2024. These advancements not only improve patient satisfaction but also attract tech-savvy millennials. Stakeholders can capitalize on this trend by investing in training for practitioners on novel technologies and partnering with tech firms for digital tools, positioning themselves as leaders in the innovation-driven Japan facial injectables market. Navigating Regulatory Hurdles in Aesthetic Innovations The Japan facial injectables market operates under a stringent regulatory environment, prioritizing patient safety while posing challenges for market entrants. The Pharmaceuticals and Medical Devices Agency (PMDA) mandates rigorous clinical trials for new products, often requiring Japan-specific data, which delays launches compared to regions like the EU. Advertising restrictions further complicate brand visibility, as clinics cannot make direct claims about treatment outcomes without substantiated evidence, impacting consumer outreach. Recent PMDA data from 2024 shows that approval times for new injectables have been reduced to an average of 10 months, down from 14 months in prior years, thanks to digital submission processes. However, only 1,200 certified dermatologists and plastic surgeons were licensed to perform advanced injectable treatments last year, limiting service availability. High-profile adverse reaction cases, such as a 2023 Tokyo incident involving off-label filler use affecting 50 patients, have tightened post-market surveillance. For stakeholders, navigating this landscape requires robust compliance strategies and investment in local clinical research. Building partnerships with certified practitioners and focusing on transparent communication can help overcome barriers in the Japan facial injectables market, ensuring trust and market penetration. Disparities in Urban and Rural Demand Patterns In the Japan facial injectables market, a significant urban-rural divide shapes demand dynamics as of 2024, driven by economic and accessibility factors. Urban hubs like Tokyo, Osaka, and Nagoya account for the majority of procedures, fueled by higher disposable incomes and exposure to global beauty trends via media. In contrast, rural regions lag due to fewer specialized clinics, lower awareness, and cultural hesitancy toward cosmetic enhancements, often viewing them as unnecessary or vain. According to a study by the Japan Cosmetic Industry Association (JCIA), Tokyo recorded over 78,000 injectable procedures last year, while rural prefectures like Shimane reported fewer than 2,000. Urban clinics also cater to convenience-driven clients, offering extended hours and premium services, with over 35,000 bookings for same-day treatments in Osaka. Rural consumers often travel to cities, facing additional costs, with travel-related expenses for treatments estimated at over US$500 per trip for 10,000 individuals in 2024. Stakeholders can address this gap by deploying mobile clinics or partnering with telemedicine platforms to offer virtual consultations. Targeted awareness campaigns highlighting safety and benefits could also boost rural adoption in the Japan facial injectables market, unlocking untapped potential. Competitive Dynamics Among Aesthetic Industry Players: Top 3 Players Control Nearly 60% Market Share The Japan facial injectables market is fiercely competitive as of 2024, with global and local players battling for dominance through innovation and brand trust. International leaders like Allergan (Botox) Galderma, and Medytox Inc leverage their extensive portfolios and global reputation, focusing on products suited for Asian facial structures. These 3 players collectively hold over 60% market share. On the other hand, domestic firms, such as Koken Co., are gaining ground with cost-effective fillers and culturally aligned marketing, appealing to price-sensitive consumers seeking trusted local brands. A 2024 report from the Japan Aesthetic Research Institute (JARI) notes that Allergan conducted over 55,000 Botox procedures last year, while Koken's fillers were used in 28,000 treatments, reflecting growing local traction. Strategic collaborations are key, with Merz partnering with 300 Tokyo clinics in 2024 for exclusive training, enhancing practitioner expertise. Local players counter with affordability, pricing treatments US$50-100 lower per session than global brands. Social media campaigns, involving over 200 influencers last year, have also become critical for brand visibility. For stakeholders, differentiating through niche offerings—like male-specific treatments or eco-friendly fillers—and building practitioner networks can secure a foothold in the dynamic Japan facial injectables market, balancing global standards with local relevance. Cultural Nuances Influencing Beauty Treatment Choices Cultural nuances profoundly influence the Japan facial injectables market as of 2024, shaping beauty perceptions and treatment choices. The Japanese ethos of 'mottainai' (avoiding waste) extends to maintaining a youthful appearance as a form of self-care and respect. Subtlety is prized, with consumers favoring injectables for minor enhancements like smoothing nasolabial folds over bold transformations, distinguishing Japan from markets like South Korea, where dramatic changes are often sought. A survey by the Japan Beauty Institute (JBI) found that 72,000 respondents preferred fillers for natural corrections, with over 40,000 treatments focusing on fine lines. J-pop and anime aesthetics drive younger demographics, with 25,000 procedures last year inspired by idol-like features. However, conservative attitudes among older generations persist, with only 15,000 clients aged 50+ opting for injectables due to stigma. Clinics in the Japan facial injectables market are reframing treatments as wellness solutions, hosting over 100 awareness seminars in 2024 to destigmatize aesthetics. Stakeholders can tap into this cultural landscape by emphasizing natural results and aligning with local beauty ideals. Tailored campaigns targeting younger and male demographics could further accelerate adoption in the market, blending tradition with modern aspirations. Economic Factors Steering Aesthetic Spending Trends Economic factors significantly impact the Japan facial injectables market as of 2024, with disposable income and cost pressures shaping consumer behavior. Japan's economy faces challenges like wage stagnation, limiting spending on non-essential services for middle- and lower-income groups. Urban professionals, however, view injectables as a career investment, prioritizing image in competitive job markets. Economic disparities thus create a segmented market where affluent areas drive the bulk of demand. A economic analysis by the Japan Finance Ministry highlights that import costs for foreign injectables rose in the facial injectables market due to a weaker yen, increasing treatment prices by US$20-30 per session in over 500 clinics. Despite this, demand in high-income Tokyo districts saw 58,000 procedures last year. Post-pandemic recovery has spurred discretionary spending, with over 30,000 young professionals using annual bonuses for aesthetics in 2024. Medical tourism, supported by government initiatives, also shows promise, with 5,000 international clients seeking treatments last year. Stakeholders can navigate economic constraints by offering tiered pricing or payment plans, ensuring accessibility. Leveraging tourism by marketing Japan as an aesthetic hub could further boost the market, aligning economic strategies with consumer realities. Need Custom Data? Let Us Know: Future Horizons for Aesthetic Treatment Innovations Looking forward, the Japan facial injectables market is poised for robust growth with emerging trends offering significant opportunities for stakeholders. Personalized treatments, aided by genetic profiling for customized fillers, are on the horizon, while male and senior demographics present untapped markets. Sustainability is also gaining traction, with biodegradable fillers attracting eco-conscious clients. The market is set to benefit from Japan's aging population, projected to drive demand for rejuvenation treatments. A forecast by the Japan Aesthetic Technology Forum predicts 45,000 users will adopt AR-based consultation tools by next year, enhancing treatment planning. Rural expansion via mobile clinics could reach 20,000 new clients annually, based on pilot programs in 2024. Global investment in Japanese aesthetic R&D is also rising, with over US$10 million allocated to local startups last year for innovative injectables. Challenges like regulatory delays and economic pressures remain, but strategic partnerships with tech firms and localized marketing can mitigate risks. For stakeholders, focusing on education, accessibility, and niche innovations—such as male-specific products—will be key to capitalizing on the evolving Japan facial injectables market, positioning Japan as a global leader in aesthetic advancements. Japan Facial Injectables Market Major Players: Galderma Allergan Aesthetics Medytox Inc. Hugel Inc. HA Derma VAIM Global Inc Other Prominent Players Key Segmentation: By Product Type Botulinum Toxin/Botox Derma Fillers Collagen Hyaluronic Acid (HA) Fat Injection Calcium Hydroxylapatite (CaHA) Poly-L-lactic Acid (PLLA) Others By Age Group 18-34 Years 35-50 Years 51+ Years By Gender Male Female By Clinic Type MedSpa Dermatology Clinics Hospitals Plastic Surgery Centers Others By Application Wrinkle Reduction Face Line Correction Lip Augmentation Face Lift Facial Contouring Acne Scar Treatment Lipoatrophy Treatment Others Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Japan Facial Injectables Market Set to Reach Valuation of US$ 1,121.31 Million by 2033
Japan facial injectables market is set to thrives with growth in natural beauty trends, technological innovations, and urban demand. Despite regulatory and rural challenges, cultural shifts and economic factors fuel sustained growth potential. Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The Japan facial injectables market was valued at US$ 508.18 million in 2024 and is projected to reach US$ 1,121.31 million by 2033, growing at a CAGR of 9.52% during the forecast period 2025–2033. The Japan facial injectables market is experiencing a significant shift in consumer behavior with a growing preference for subtle, natural-looking enhancements over dramatic transformations. Younger demographics, particularly those in their 20s and 30s, are increasingly opting for preventative treatments like botulinum toxin to delay signs of aging. Social media platforms, such as Instagram and TikTok, play a pivotal role in shaping beauty ideals, with influencers promoting injectables as a routine part of self-care. Moreover, there is a noticeable rise in male consumers seeking facial injectables, driven by societal acceptance of male grooming and professional competitiveness. Request Sample Pages: This trend aligns with Japan's cultural emphasis on "kawaii" (cuteness) and polished aesthetics, pushing demand for products that enhance facial harmony. According to a 2024 survey by the Japan Aesthetic Medicine Association, over 60,000 men underwent injectable treatments last year, a sharp increase from previous years. Clinics in urban hubs like Tokyo and Osaka report a surge in demand for hyaluronic acid fillers for jawline contouring and under-eye rejuvenation. Additionally, the rise of hybrid work environments has reduced downtime concerns, encouraging more individuals to schedule quick procedures. As consumer awareness grows, brands are focusing on personalized treatment plans, ensuring safety and satisfaction in this evolving landscape of the Japan facial injectables market. Key Findings in Japan Facial Injectables Market Market Forecast (2033) US$1,121.31 million CAGR 9.52% By Product Type Botulinum Toxin/Botox (55.97%) By Age Group 35-50 Year (51.72%) By Gender Female (81.62%) By Clinic Type Dermatology Clinics (35.45%) By Application Wrinkle Reduction (39.97%) Top Drivers Japan's rapidly aging society seeking non-surgical facial rejuvenation solutions Growing acceptance of aesthetic procedures among younger Japanese professionals Advanced injection techniques developed specifically for Asian facial anatomy Top Trends Micro-dosing approaches gaining popularity for natural-looking results in Japan Preventative treatments starting earlier among Tokyo millennials and Gen-Z AI-powered facial analysis integration in Japanese aesthetic clinics nationwide Top Challenges Strict PMDA regulations limiting new product approvals and innovations High training requirements creating certified injector shortages across prefectures Price sensitivity among middle-income consumers limiting market expansion potential Technological Breakthroughs Redefining Aesthetic Treatments In the Japan facial injectables market, technological innovation is a key growth driver with new formulations and delivery methods enhancing treatment precision and outcomes. Advanced micro-droplet injection techniques are gaining popularity for their ability to deliver natural-looking results, particularly for delicate areas like under-eyes. Additionally, AI-powered consultation tools are transforming patient experiences, enabling simulations of post-treatment results. Major brands are also developing longer-lasting fillers with biocompatible materials tailored to Asian skin types. A report by the Japan Society of Aesthetic Surgery (JSAS) indicates that over 92,000 procedures utilized cutting-edge injection technologies last year, reflecting rapid market adoption. For instance, Galderma's latest hyaluronic acid filler, designed for thinner skin textures common in Japanese patients, saw over 30,000 applications in clinics nationwide. The rise of telemedicine platforms has further democratized access, with over 25,000 virtual consultations recorded for injectables in 2024. These advancements not only improve patient satisfaction but also attract tech-savvy millennials. Stakeholders can capitalize on this trend by investing in training for practitioners on novel technologies and partnering with tech firms for digital tools, positioning themselves as leaders in the innovation-driven Japan facial injectables market. Navigating Regulatory Hurdles in Aesthetic Innovations The Japan facial injectables market operates under a stringent regulatory environment, prioritizing patient safety while posing challenges for market entrants. The Pharmaceuticals and Medical Devices Agency (PMDA) mandates rigorous clinical trials for new products, often requiring Japan-specific data, which delays launches compared to regions like the EU. Advertising restrictions further complicate brand visibility, as clinics cannot make direct claims about treatment outcomes without substantiated evidence, impacting consumer outreach. Recent PMDA data from 2024 shows that approval times for new injectables have been reduced to an average of 10 months, down from 14 months in prior years, thanks to digital submission processes. However, only 1,200 certified dermatologists and plastic surgeons were licensed to perform advanced injectable treatments last year, limiting service availability. High-profile adverse reaction cases, such as a 2023 Tokyo incident involving off-label filler use affecting 50 patients, have tightened post-market surveillance. For stakeholders, navigating this landscape requires robust compliance strategies and investment in local clinical research. Building partnerships with certified practitioners and focusing on transparent communication can help overcome barriers in the Japan facial injectables market, ensuring trust and market penetration. Disparities in Urban and Rural Demand Patterns In the Japan facial injectables market, a significant urban-rural divide shapes demand dynamics as of 2024, driven by economic and accessibility factors. Urban hubs like Tokyo, Osaka, and Nagoya account for the majority of procedures, fueled by higher disposable incomes and exposure to global beauty trends via media. In contrast, rural regions lag due to fewer specialized clinics, lower awareness, and cultural hesitancy toward cosmetic enhancements, often viewing them as unnecessary or vain. According to a study by the Japan Cosmetic Industry Association (JCIA), Tokyo recorded over 78,000 injectable procedures last year, while rural prefectures like Shimane reported fewer than 2,000. Urban clinics also cater to convenience-driven clients, offering extended hours and premium services, with over 35,000 bookings for same-day treatments in Osaka. Rural consumers often travel to cities, facing additional costs, with travel-related expenses for treatments estimated at over US$500 per trip for 10,000 individuals in 2024. Stakeholders can address this gap by deploying mobile clinics or partnering with telemedicine platforms to offer virtual consultations. Targeted awareness campaigns highlighting safety and benefits could also boost rural adoption in the Japan facial injectables market, unlocking untapped potential. Competitive Dynamics Among Aesthetic Industry Players: Top 3 Players Control Nearly 60% Market Share The Japan facial injectables market is fiercely competitive as of 2024, with global and local players battling for dominance through innovation and brand trust. International leaders like Allergan (Botox) Galderma, and Medytox Inc leverage their extensive portfolios and global reputation, focusing on products suited for Asian facial structures. These 3 players collectively hold over 60% market share. On the other hand, domestic firms, such as Koken Co., are gaining ground with cost-effective fillers and culturally aligned marketing, appealing to price-sensitive consumers seeking trusted local brands. A 2024 report from the Japan Aesthetic Research Institute (JARI) notes that Allergan conducted over 55,000 Botox procedures last year, while Koken's fillers were used in 28,000 treatments, reflecting growing local traction. Strategic collaborations are key, with Merz partnering with 300 Tokyo clinics in 2024 for exclusive training, enhancing practitioner expertise. Local players counter with affordability, pricing treatments US$50-100 lower per session than global brands. Social media campaigns, involving over 200 influencers last year, have also become critical for brand visibility. For stakeholders, differentiating through niche offerings—like male-specific treatments or eco-friendly fillers—and building practitioner networks can secure a foothold in the dynamic Japan facial injectables market, balancing global standards with local relevance. Cultural Nuances Influencing Beauty Treatment Choices Cultural nuances profoundly influence the Japan facial injectables market as of 2024, shaping beauty perceptions and treatment choices. The Japanese ethos of 'mottainai' (avoiding waste) extends to maintaining a youthful appearance as a form of self-care and respect. Subtlety is prized, with consumers favoring injectables for minor enhancements like smoothing nasolabial folds over bold transformations, distinguishing Japan from markets like South Korea, where dramatic changes are often sought. A survey by the Japan Beauty Institute (JBI) found that 72,000 respondents preferred fillers for natural corrections, with over 40,000 treatments focusing on fine lines. J-pop and anime aesthetics drive younger demographics, with 25,000 procedures last year inspired by idol-like features. However, conservative attitudes among older generations persist, with only 15,000 clients aged 50+ opting for injectables due to stigma. Clinics in the Japan facial injectables market are reframing treatments as wellness solutions, hosting over 100 awareness seminars in 2024 to destigmatize aesthetics. Stakeholders can tap into this cultural landscape by emphasizing natural results and aligning with local beauty ideals. Tailored campaigns targeting younger and male demographics could further accelerate adoption in the market, blending tradition with modern aspirations. Economic Factors Steering Aesthetic Spending Trends Economic factors significantly impact the Japan facial injectables market as of 2024, with disposable income and cost pressures shaping consumer behavior. Japan's economy faces challenges like wage stagnation, limiting spending on non-essential services for middle- and lower-income groups. Urban professionals, however, view injectables as a career investment, prioritizing image in competitive job markets. Economic disparities thus create a segmented market where affluent areas drive the bulk of demand. A economic analysis by the Japan Finance Ministry highlights that import costs for foreign injectables rose in the facial injectables market due to a weaker yen, increasing treatment prices by US$20-30 per session in over 500 clinics. Despite this, demand in high-income Tokyo districts saw 58,000 procedures last year. Post-pandemic recovery has spurred discretionary spending, with over 30,000 young professionals using annual bonuses for aesthetics in 2024. Medical tourism, supported by government initiatives, also shows promise, with 5,000 international clients seeking treatments last year. Stakeholders can navigate economic constraints by offering tiered pricing or payment plans, ensuring accessibility. Leveraging tourism by marketing Japan as an aesthetic hub could further boost the market, aligning economic strategies with consumer realities. Need Custom Data? Let Us Know: Future Horizons for Aesthetic Treatment Innovations Looking forward, the Japan facial injectables market is poised for robust growth with emerging trends offering significant opportunities for stakeholders. Personalized treatments, aided by genetic profiling for customized fillers, are on the horizon, while male and senior demographics present untapped markets. Sustainability is also gaining traction, with biodegradable fillers attracting eco-conscious clients. The market is set to benefit from Japan's aging population, projected to drive demand for rejuvenation treatments. A forecast by the Japan Aesthetic Technology Forum predicts 45,000 users will adopt AR-based consultation tools by next year, enhancing treatment planning. Rural expansion via mobile clinics could reach 20,000 new clients annually, based on pilot programs in 2024. Global investment in Japanese aesthetic R&D is also rising, with over US$10 million allocated to local startups last year for innovative injectables. Challenges like regulatory delays and economic pressures remain, but strategic partnerships with tech firms and localized marketing can mitigate risks. For stakeholders, focusing on education, accessibility, and niche innovations—such as male-specific products—will be key to capitalizing on the evolving Japan facial injectables market, positioning Japan as a global leader in aesthetic advancements. Japan Facial Injectables Market Major Players: Galderma Allergan Aesthetics Medytox Inc. Hugel Inc. HA Derma VAIM Global Inc Other Prominent Players Key Segmentation: By Product Type Botulinum Toxin/Botox Derma Fillers Collagen Hyaluronic Acid (HA) Fat Injection Calcium Hydroxylapatite (CaHA) Poly-L-lactic Acid (PLLA) Others By Age Group 18-34 Years 35-50 Years 51+ Years By Gender Male Female By Clinic Type MedSpa Dermatology Clinics Hospitals Plastic Surgery Centers Others By Application Wrinkle Reduction Face Line Correction Lip Augmentation Face Lift Facial Contouring Acne Scar Treatment Lipoatrophy Treatment Others Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio
Yahoo
an hour ago
- Yahoo
NIH employees publish ‘Bethesda Declaration' in dissent of Trump administration policies
In October 2020, two months before Covid-19 vaccines would become available in the US, Stanford health policy professor Dr. Jay Bhattacharya and two colleagues published an open letter calling for a contrarian approach to managing the risks of the pandemic: protecting the most vulnerable while allowing others largely to resume normal life, aiming to obtain herd immunity through infection with the virus. They called it the Great Barrington Declaration, for the Massachusetts town where they signed it. Backlash to it was swift, with the director-general of the World Health Organization calling the idea of allowing a dangerous new virus to sweep through unprotected populations 'unethical.' Bhattacharya later testified before Congress that it – and he – immediately became targets of suppression and censorship by those leading scientific agencies. Now, Bhattacharya is the one in charge, and staffers at the agency he leads, the US National Institutes of Health, published their own letter of dissent, taking issue with what they see as the politicization of research and destruction of scientific progress under the Trump administration. They called it the Bethesda Declaration, for the location of the NIH. 'We hope you will welcome this dissent, which we modeled after your Great Barrington Declaration,' the staffers wrote. The letter was signed by more than 300 employees across the biomedical research agency, according to the non-profit organization Stand Up for Science, which also posted it; while many employees signed anonymously because of fears of retaliation, nearly 100 - from graduate students to division chiefs - signed by name. It comes the day before Bhattacharya is due to testify before Congress once more, in a budget hearing to be held Tuesday by the Senate appropriations committee. It's just the latest sign of strife from inside the NIH, where some staff last month staged a walkout of a townhall with Bhattacharya to protest working conditions and an inability to discuss them with the director. 'If we don't speak up, we allow continued harm to research participants and public health in America and across the globe,' said Dr. Jenna Norton, a program officer at the National Institute of Diabetes and Digestive and Kidney Diseases and a lead organizer of the Declaration, in a news release from Stand Up for Science. She emphasized she was speaking in a personal capacity, not on behalf of the NIH. The letter, which the staffers said they also sent to US Department of Health and Human Services Secretary Robert F. Kennedy Jr. and members of Congress who oversee the NIH, urged Bhattacharya to 'restore grants delayed or terminated for political reasons so that life-saving science can continue,' citing work in areas including health disparities, Covid-19, health impacts of climate change and others. They cited findings by two scientists that said about 2,100 NIH grants for about $9.5 billion have been terminated since the second Trump administration began. The NIH budget had been about $48 billion annually, and the Trump administration has proposed cutting it next year by about 40%. The research terminations 'throw away years of hard work and millions of dollars,' the NIH staffers wrote. 'Ending a $5 million research study when it is 80% complete does not save $1 million, it wastes $4 million.' They also urged Bhattacharya to reverse a policy that aims to implement a new, and lower, flat 15% rate for paying for indirect costs of research at universities, which supports shared lab space, buildings, instruments and other infrastructure, as well as the firing of essential NIH staff. Those who wrote the Bethesda Declaration were joined Monday by outside supporters, in a second letter posted by Stand Up for Science and signed by members of the public, including more than a dozen Nobel Prize-winning scientists. 'We urge NIH and Department of Health and Human Services (HHS) leadership to work with NIH staff to return the NIH to its mission and to abandon the strategy of using NIH as a tool for achieving political goals unrelated to that mission,' they wrote. The letter called for the grant-making process to be conducted by scientifically trained NIH staff, guided by rigorous peer review, not by 'anonymous individuals outside of NIH.' It also challenged assertions put forward by Kennedy, who often compares today's health outcomes with those around the time his uncle John F. Kennedy was president, in the early 1960s. 'Since 1960, the death rate due to heart disease has been cut in half, going from 560 deaths per 100,000 people to approximately 230 deaths per 100,000 today,' they wrote. 'From 1960 to the present day, the five-year survival rate for childhood leukemia has increased nearly 10-fold, to over 90% for some forms. In 1960, the rate of measles infection was approximately 250 cases per 100,000 people compared with a near zero rate now (at least until recently).' They acknowledged there's still much work to do, including addressing obesity, diabetes and opioid dependency, 'but,' they wrote, 'glamorizing a mythical past while ignoring important progress made through biomedical research does not enhance the health of the American people.' Support from the NIH, they argued, made the US 'the internationally recognized hub for biomedical research and training,' leading to major advances in improving human health. 'I've never heard anybody say, 'I'm just so frustrated that the government is spending so much money on cancer research, or trying to address Alzheimer's,' ' said Dr. Jeremy Berg, who organized the letter of outside support and previously served as director of the National Institute of General Medical Sciences at the NIH. 'Health concerns are a universal human concern,' Berg told CNN. 'The NIH system is not perfect by any stretch of the imagination, but has been unbelievably productive in terms of generating progress on specific diseases.'